AstraZeneca commissioned CRA to investigate the economic and societal burden associated with Acute Coronary Syndromes (ACS). Our Life Sciences specialists analyzed occurrences of ACS in the United Kingdom, treatment cost of ACS in the United Kingdom, economic cost of ACS, and the total burden of disease associated with ACS. This short paper represents a summary of the full report.
Policy solutions to improve access to fertility treatment and optimise patient care: consensus from an expert forum
Infertility affects more than 17% of people of reproductive age globally, yet access to ART remains uneven and often out of reach.